Cryptococcosis

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Monday, February 26, 2024
Infection, Bangladesh Technical Education Board, Division, Amphotericin B, Palliative care, Recurrence, University, Doctor of Philosophy, Malignancy, Nationwide, Physician, City, Azole, Hospital, Cryptococcosis, Nephrotoxicity, Skin, Aspergillosis, Fusarium, Lung, Fungal infection, Johns Hopkins, Vanderbilt University Medical Center, LNC, Coccidioides, Patient, Coccidioidomycosis, Histoplasmosis, Brain, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Retrieved on: 
Tuesday, February 20, 2024
FDA, Food, Safety, Element, LNC, Patient, Probability, HIV, Cryptococcosis, Partnership, Pharmaceutical industry

BEDMINSTER, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces alignment with the U.S. Food and Drug Administration (FDA) on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited treatment options (the “ORALTO” trial).

Key Points: 
  • “We are pleased to achieve alignment with the FDA on the design of a single Phase 3 trial to support the registration of MAT2203 for the treatment of invasive aspergillosis in patients with limited treatment options,” commented Dr. Theresa Matkovits, Chief Development Officer at Matinas.
  • “We greatly appreciate the opportunity to work collaboratively with the FDA, which was essential for reaching consensus on all critical elements of the registrational path for MAT2203.
  • “We are energized by the support and guidance from the FDA, and believe this alignment provides the requisite certainty to advance our partnership discussions for this important product.
  • We are pursuing every opportunity to secure a partner and to advance MAT2203 into this Phase 3 registration trial as quickly as possible.”

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Retrieved on: 
Monday, January 8, 2024
Blood pressure, Medical Subject Headings, Marketing, CYP2C9, Agency, INN, Immune system, Lymph, Woman, Movement, Allergy, Heart rate, ATC, Multiple sclerosis, Cryptococcosis, Hypertension, International, Spinal cord, Disease, Headache, Parent, Blood, Language, SPMS, Brain, Cancer, Inflammation, Stroke, Liver, Cardiology, DSM-IV codes, Pregnancy, European Medicines Agency, Lymphocyte, Infection, Tablet, EDSS, EMEA, Select, Cell, Patient, Birth, Checklist, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Mayzent, siponimod, Date of authorisation: 13/01/2020, Revision: 11, Status: Authorised

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases

Retrieved on: 
Tuesday, August 22, 2023
Infectious Diseases Society of America, University, Survival, Infection, Toxicity, LNC, IDSA, Trial of the century, Cryptococcosis, Patient, University of Minnesota Medical School, Fungal infection, MPH, Enactment, NYSE, Pharmaceutical industry, MD

While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.

Key Points: 
  • While further clinical trials are needed in other fungal conditions, the EnACT trial establishes proof of concept for the safe and effective treatment of invasive fungal infections.
  • In this randomized trial of 141 HIV-positive individuals afflicted by life-threatening cryptococcal meningitis, the oral amphotericin MAT2203 product combined with oral flucytosine appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than intravenous amphotericin B.
  • The publication of the EnACT data in Clinical Infectious Diseases is yet another milestone for our development program.
  • We would like to thank all the EnACT participants, our dedicated investigators, and the entire clinical study team in Uganda for their commitment to this important clinical trial.”

Fungal infections in the brain aren't just the stuff of movies – Africa grapples with a deadly epidemic

Retrieved on: 
Thursday, July 13, 2023
Gaps, Review, Infection, Canker, Pressure, Human, Fungal infection, HIV, Atmosphere, Culture, Health care, Pneumocystis jirovecii, Fever, Cough, Immunodeficiency, Inflammation, Cryptococcosis, Brain, Research, COVID, Mucormycosis, Fungus, Facial, Thermoregulation, Death, Climate change, The Last of Us, Soil, Patient, Population, Risk, Cryptococcus neoformans, Pneumocystidomycetes, Immune system, Lower respiratory tract infection, Steroid, Diagnosis, Flucytosine, Health, Environment, Meningitis, Cryptococcus, Pneumonia, Skin, Disease, Truffle, Pharmaceutical industry, Vaccine

I am a neurobiologist who has been studying fungal infections of the brain for 10 years.

Key Points: 
  • I am a neurobiologist who has been studying fungal infections of the brain for 10 years.
  • I was part of a team that recently published a review discussing the emergence, and re-emergence, of fungal infections in Africa, especially in sub-Saharan Africa.
  • We conclude that Africa is suffering from a silent, but costly, epidemic of fungal infections.

What are fungal infections?

    • For the greater part of the history of humankind, fungal infections were never a threat to human health.
    • Even then, our immune systems are quite capable of fighting against fungal infections.
    • Africa accounts for 67% of the global burden of HIV, and opportunistic fungal diseases are on the rise.

Some examples

    • Today, sub-Saharan Africa contributes about 73% of all global cases and deaths resulting from the disease.
    • Cryptococcal meningitis is caused by the fungus Cryptococcus neoformans, which is found in soil and bird droppings.
    • It first leads to the development of a lung infection and later a fatal brain infection.
    • Cryptococcal meningitis is a leading cause of adult meningitis in sub-Saharan Africa and it’s associated with almost 20% of all AIDS-related deaths.

Growing burden

    • While these factors are not unique to Africa, the burden of fungal diseases and the number of people who succumb to them is much greater.
    • The COVID pandemic seems to have made the global fungal burden worse.
    • COVID-induced lung damage, high blood sugar, and the steroids often used to treat it are all predisposing factors to black fungus infection.

But don’t we have antifungal drugs?

    • With poorly funded and overburdened healthcare systems, many African countries are not well prepared to deal with fungal infections.
    • Additionally, some of the WHO-recommended antifungal drugs – such as flucytosine – are unavailable in most African countries.

Management strategies


    Fungal threats are adding pressure to overburdened health systems with a limited arsenal of treatment options. Healthcare professionals, scientific researchers, policymakers and governments must address the gaps in the diagnosis and management of fungal infections. This will help to improve capacity to deal with them.

Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update

Retrieved on: 
Wednesday, March 15, 2023
Transfer, Research, Biomedical Advanced Research and Development Authority, Messenger, Bangladesh Technical Education Board, NYSE, LNC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MedImmune, Inc. v. Genentech, Inc., BARDA, Partnership, NIH, Dicarboxylic acid, National Resilience Institute, Patient, BioNTech, Oligonucleotide, FDA, Development, Cryptococcosis, ASO, Evaluation, Safety, Clinical trial, RNA, Conference call, Enactment, Food, Small RNA, Pharmaceutical industry, Vaccine, Cryptocurrency, Conference

BEDMINSTER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2022 financial results and provides a business update.

Key Points: 
  • Conference call and webcast begin at 4:30 p.m. Eastern time today
    BEDMINSTER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, reports 2022 financial results and provides a business update.
  • “Phase 2 MAT2203 clinical trial results demonstrated the ability of our platform to efficaciously deliver a safe, well-tolerated oral form of amphotericin B with dramatic survival results.
  • Results from in vitro testing under a Material Transfer and Evaluation Agreement with National Resilience, which was announced in January 2023.
  • Matinas will host a conference call and webcast today beginning at 4:30 p.m. Eastern time.

Innovation Pharmaceuticals Announces New Antifungal Testing of Brilacidin by NIH/NIAID-Affiliated and Other Academic Researchers

Retrieved on: 
Wednesday, March 15, 2023
Research, Conference, Histoplasma capsulatum, Mortality, Fungal infection, Pseudallescheria boydii, Voriconazole, São Paulo, Amphotericin B, Immunology, USP, Gordon Research Conferences, Biology, Caspofungin, Fungal keratitis, Micafungin, World Health Organization, Fungus, Fluconazole, Cryptococcosis, OTCQB, Posaconazole, News, University, Pharmaceutical industry, Vaccine, Antibiotics, Mucorales

Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.

Key Points: 
  • Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed.
  • USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi.
  • Beyond Brilacidin’s broad-spectrum ability to directly inhibit fungal pathogens, Brilacidin may favorably modulate the host response to fungal infections.
  • Corresponding posters for these conferences are available on the Events and Presentations section of the Company’s website at the link below.

Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID

Retrieved on: 
Thursday, March 2, 2023
NYSE, Doctor of Philosophy, European, Internal medicine, Fungal infection, Toxicity, ECCMID, University, Drug development, Patient, Cryptococcosis, Infection, Congress, Amphotericin B, AMB, LNC, Enactment, MPH, Division, Cell, Principal, Pharmaceutical industry, MD, Medicine

The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.

Key Points: 
  • The hybrid in-person and virtual Congress is being held April 15-18 in Copenhagen and the MAT2203 presentations will both take place on April 18.
  • “Calcaneal Rhodotorula mucilaginosa osteomyelitis treated with oral amphotericin B (MAT2203)” - Senior Author, Marisa H. Miceli, MD, Professor of Medicine, Specializing in Fungal Infections and Transplant Diseases, Division of Infectious Diseases, Internal Medicine, at the University of Michigan.
  • MAT2203 reduces systemic toxicity by directing amphotericin B to targeted cells at sites of infection, supporting a favorable safety profile relative to IV-administered AMB with the additional benefit of oral administration.
  • “We believe that our delivery platform holds promise for the targeted delivery of gene therapy, providing Matinas with the opportunity to develop robust internal and partnered drug development candidates.”

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023
Transfer, Biomedical Advanced Research and Development Authority, RNA, Necessity and sufficiency, Disease, Lipofectamine, Food, Phase II, Safety, Oligonucleotide, Mycosis, Attention, HeLa, Mucormycosis, NYSE, BioNTech, Gene expression, Evaluation, Mucor, Sirna, Vaccine, ASO, Cryptococcosis, Aspergillosis, Survival, Therapy, Conference, Gilead, BARDA, Internal, COVID, HEK293, Patient, Enactment, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Aspergillus, LNC, Organic acid, Hand, Candidiasis, Genentech, Coccidioidomycosis, Medicine, Asos, Development, RNA transfection, Sirna Therapeutics, Toxicity, Fine chemical, Pharmaceutical industry, Matina Brothers

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

Retrieved on: 
Wednesday, January 11, 2023
Cryptococcosis, SAB, CLK, TARGET, Merck, New Drug Application, Staphylococcus aureus, FGFR, Regulation of tobacco by the U.S. Food and Drug Administration, Aspergillosis, CHF, PARG, DXR, Mucormycosis, Marketing, BARDA, Growth, Food, Subclinical infection, Patient, Research, ABSSSI, Glioblastoma, Gram-negative bacteria, Ceftobiprole, LR, Pharmaceutical industry, Vaccine, Isavuconazonium, EU

CHF 122 million, exceeding guidance by more than 17%

Key Points: 
  • CHF 122 million, exceeding guidance by more than 17%
    Ad hoc announcement pursuant to Art.
  • Revenue contributions from the antifungal Cresemba and the antibiotic Zevtera are expected to amount to approximately CHF 122 million (full-year 2022 guidance: CHF 98 million – 104 million).
  • David Veitch, Chief Executive Officer, commented: “We achieved significant milestones in 2022 and will continue to focus on delivering on our strategy to drive value creation going forwards.
  • By November 2022, Basilea had entered into three separate transactions with innovative oncology companies.